JNJJanssen Research & Development, LLCRunning, no new patients
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 419 (final count)
- Started
- Jun 12, 2020
- Main results expected
- May 1, 2024
- Fully finished
- Mar 31, 2027
- Results posted
- May 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04181827 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC